Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review [0.03%]
欧洲和美国部分国家的生物类似药个体处方激励措施的综述性文献研究
Félix Lobo,Isabel Río-Álvarez,Ángeles Flores
Félix Lobo
The uptake of biosimilar medicines in Europe and the USA remains highly variable and at times slow, despite the significant potential for cost savings for both patients and healthcare systems. One of the most recommended measures to address...
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study [0.03%]
乌司奴单抗相似药免疫原性对比研究中仅需生物分析数据及单剂量PK数据：乌司奴单抗案例研究
Martin Schiestl,Nivedita Roy,Michael Trieb et al.
Martin Schiestl et al.
Comparative immunogenicity is a key regulatory requirement for biosimilars. In a streamlined biosimilar development process, absent a comparative clinical efficacy study, the analytical data and clinical pharmacokinetics (PK) study need to ...
Lipid-Lowering RNA Therapeutics for Atherosclerotic Cardiovascular Disease Prevention: A State-of-the-Art Review [0.03%]
用于动脉粥样硬化性心血管疾病预防的降脂RNA药物疗法：最新研究进展述评
Samuel D Maidman,Robert S Rosenson
Samuel D Maidman
Despite the modern era of effective and safe high-intensity statins and non-statin agents, a significant portion of patients are still unable to achieve guideline-recommended lipid goals for the prevention of atherosclerotic cardiovascular ...
Influence of Pharmacokinetic-Pharmacodynamic Failure Mechanisms on Outcomes in Biologic Therapy Sequencing in Inflammatory Bowel Disease: A Retrospective Cohort Study [0.03%]
炎性肠病生物制剂序贯治疗中药代动力学-药效学失败机制对疗效影响的回顾性队列研究
Casper Steenholdt,Ruben Due Lorentsen,Jon Henneberg et al.
Casper Steenholdt et al.
Background: Increasing therapeutic options for inflammatory bowel disease calls for tools to aid choice of sequencing. We investigated if pharmacokinetic (PK) and pharmacodynamic (PD) failure mechanisms prompting therapy ...
Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review" [0.03%]
对“PEG化蛋白质药物的不良影响：一次目标文献回顾”的评论
Joao Goncalves,Paolo Caliceti
Joao Goncalves
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders [0.03%]
神经肌炎谱系障碍中靶向单克隆抗体的新兴作用
Angela H Holian,Brian G Weinshenker
Angela H Holian
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease that results in recurring, often severe attacks on the optic nerves and spinal cord that may result in profound visual loss and paralysis. Since the late 1990s, NM...
Shoaib Ugradar,Emanuil Parunakian,Raymond S Douglas
Shoaib Ugradar
Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves' disease. It is an autoimmune disorder that may present with signs of inflammation and extracellular matrix modification, leading to the characteristic feat...
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings [0.03%]
超越成本：生物类似药在真实世界临床和患者获益的观察
Tore K Kvien,Neil Betteridge,Ines Brückmann et al.
Tore K Kvien et al.
The introduction of biosimilars into healthcare systems globally is recognized by many as a healthcare success. Despite this, questions have been raised about whether biosimilars can deliver sufficient value to patients and healthcare profe...
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy [0.03%]
骨关节炎的新兴疗法：间充质干细胞、细胞外小泡和使用水凝胶增强疗效
Qiming Pang,Jingdi Zhan,Zhuolin Chen et al.
Qiming Pang et al.
Osteoarthritis is a prevalent condition among middle-aged and elderly populations characterized primarily by the progressive degeneration of articular cartilage. Despite advances in medical technology, the complexity of osteoarthritis patho...